Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Receivables (2020 - 2024)

Historic Change in Receivables for Janux Therapeutics (JANX) over the last 5 years, with Q2 2024 value amounting to $7.0 million.

  • Janux Therapeutics' Change in Receivables rose 103080.0% to $7.0 million in Q2 2024 from the same period last year, while for Jun 2025 it was $7.5 million, marking a year-over-year increase of 1111.11%. This contributed to the annual value of -$8.0 million for FY2021, which is 20000.0% down from last year.
  • Janux Therapeutics' Change in Receivables amounted to $7.0 million in Q2 2024, which was up 103080.0% from $519000.0 recorded in Q1 2024.
  • Over the past 5 years, Janux Therapeutics' Change in Receivables peaked at $8.0 million during Q4 2020, and registered a low of -$7.6 million during Q1 2021.
  • Over the past 5 years, Janux Therapeutics' median Change in Receivables value was $500000.0 (recorded in 2022), while the average stood at $833333.3.
  • The largest annual percentage gain for Janux Therapeutics' Change in Receivables in the last 5 years was 103080.0% (2024), contrasted with its biggest fall of 3080.0% (2024).
  • Quarter analysis of 5 years shows Janux Therapeutics' Change in Receivables stood at $8.0 million in 2020, then plummeted by 104.69% to -$375000.0 in 2021, then crashed by 33.33% to -$500000.0 in 2022, then tumbled by 50.0% to -$750000.0 in 2023, then skyrocketed by 1030.8% to $7.0 million in 2024.
  • Its Change in Receivables was $7.0 million in Q2 2024, compared to $519000.0 in Q1 2024 and -$750000.0 in Q2 2023.